2 leading researchers to be honored at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium

November 29, 2012

SAN ANTONIO -- The 2012 CTRC-AACR San Antonio Breast Cancer Symposium will honor two leading breast cancer researchers during its 35th annual symposium, which will be held here Dec. 4-8 at the Henry B. Gonzales Convention Center.

Kornelia Polyak, M.D., Ph.D., will receive the 2012 AACR Outstanding Investigator Award for Breast Cancer Research, and Mina J. Bissell, Ph.D., will present the 2012 AACR Distinguished Lectureship in Breast Cancer Research.

Hosted by the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio, the AACR and Baylor College of Medicine, the symposium is a four-day program that presents a balance of clinical, translational and basic research focused on breast cancer. It provides a forum for interaction, communication and education for a broad spectrum of researchers, health care professionals and those with a special interest in breast cancer.

2012 AACR Outstanding Investigator Award for Breast Cancer Research, funded by Susan G. Komen for the Cure

Polyak will deliver her award lecture, "Breast Tumor Evolution: Drivers and Clinical Relevance," on Thursday, Dec. 6 at 11:30 a.m. CT in Exhibit Hall D of the Henry B. Gonzalez Convention Center.

Polyak is a professor of medicine in the department of medical oncology at the Dana-Farber Cancer Institute and Harvard Medical School in Boston, Mass. Her laboratory investigates the molecular basis of breast tumor evolution, with special emphasis on the role of the microenvironment and intratumor diversity in these processes. Her work focuses on identifying molecular alterations between normal and cancerous breast tissue using various technologies, determining their consequences and utilizing them to improve the clinical management of patients with breast cancer.

Funded by Susan G. Komen for the Cure, this award recognizes an investigator younger than 50 whose novel and significant work has had or may have a far-reaching impact on the etiology, detection, diagnosis, treatment or prevention of breast cancer.

2012 AACR Distinguished Lectureship in Breast Cancer Research, Supported by Bristol-Myers Squibb

Bissell will deliver her award lecture, titled "Genes and the Microenvironment: The Two Faces of Breast Cancer," on Friday, Dec. 7 at 11:30 a.m. CT in Exhibit Hall D of the Henry B. Gonzales Convention Center.

Bissell is a distinguished scientist at Lawrence Berkeley National Laboratory in Berkeley, Calif. Her innovative breast cancer research has had a profound influence on the understanding of cancer biology, in particular how three-dimensional organ architecture is responsible for normal behavior and how the loss of this crucial information influences the genesis of tumors. Her work demonstrated the pivotal role of reciprocal signaling between the nucleus and the extracellular matrix that surrounds tissues. She argued that it is the imbalance of this dynamic exchange of information that causes cancer. The research generated by Bissell and her team indicates that it is not only the genetic mutations that drive cancer, but also disruption of microenvironmental control.

Supported by Bristol-Myers Squibb, this lectureship was established in 2008 and is given annually to an individual who has undertaken outstanding scientific research that has inspired or has the potential to inspire new perspectives on the etiology, diagnosis, treatment or prevention of breast cancer.
-end-
The mission of the CTRC-AACR San Antonio Breast Cancer Symposium is to produce a unique and comprehensive scientific meeting that encompasses the full spectrum of breast cancer research, facilitating the rapid translation of new knowledge into better care for patients with breast cancer. The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio, the American Association for Cancer Research (AACR) and Baylor College of Medicine are joint sponsors of the San Antonio Breast Cancer Symposium. This collaboration utilizes the clinical strengths of the CTRC and Baylor and the AACR's scientific prestige in basic, translational and clinical cancer research to expedite the delivery of the latest scientific advances to the clinic. For more information about the symposium, please visit www.sabcs.org.

American Association for Cancer Research

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.